Sign in or create an account to add this stock to your watchlist.
About Advaxis (NASDAQ:ADXS)
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-0.78
Forward P/E Ratio-1.04
Sales & Book Value
Annual Sales$12.03 million
Price / Sales7.83
Price / CashN/A
Book Value$1.32 per share
Price / Book1.36
EPS (Most Recent Fiscal Year)($2.31)
Return on Equity-149.14%
Return on Assets-92.30%
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis (NASDAQ:ADXS) released its quarterly earnings data on Monday, March, 12th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.06. The biotechnology company had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.03 million. Advaxis had a negative net margin of 940.64% and a negative return on equity of 149.14%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
2 analysts have issued twelve-month target prices for Advaxis' shares. Their forecasts range from $5.00 to $6.00. On average, they anticipate Advaxis' share price to reach $5.50 in the next twelve months. View Analyst Ratings for Advaxis.
What are Wall Street analysts saying about Advaxis stock?
Here are some recent quotes from research analysts about Advaxis stock:
- 1. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] ADXS-NEO Can Incite Immune Responses With Non-Immunogenic" Antigens; Reiterate Buy ADXS-NEO demonstrates potential in two preclinical studies. On April 16, Advaxis presented results from two preclinical studies of ADXS-NEO at the 2018 American Association for Cancer Research (AACR) Annual Meeting. Recall, ADXS-NEO is a personalized therapy targeting tumor neoantigens developed from Advaxis’ Lm-LLO listeria delivery platform. ADXS-NEO was licensed to Amgen (AMGN; not rated) in 2016 for $40M upfront and up to $475M in development, regulatory and sales milestone payments and up to mid-double-digit royalties on worldwide sales. In the first of the two studies, the company demonstrated that ADXS-NEO is able to target frameshift mutations and drive a neoantigen-specific antitumor immune response in MC38 and CT26 mouse tumor models." (4/17/2018)
- 2. Cantor Fitzgerald analysts commented, "Multiple inflection points expected in 2018, including an update on the AIM2CERV Phase III study and potential preliminary data from Part B of the Phase I/II study of ADXS-PSA in combination with Keytruda." (9/25/2017)
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include Tyme Technologies (TYME), Dermira (DERM), Innovate (INNT), Strongbridge Biopharma (SBBP), Bellicum Pharmaceuticals (BLCM), Minerva Neurosciences (NERV), Athersys (ATHX), Seres Therapeutics (MCRB), Corbus Pharmaceuticals (CRBP), Unum Therapeutics (UMRX), Corvus Pharmaceuticals (CRVS), Catalyst Pharmaceuticals (CPRX), Paratek Pharmaceuticals (PRTK), DURECT (DRRX) and Arbutus Biopharma (ABUS).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Ms. Sara M. Bonstein, Exec. VP, Principal Accounting Officer, CFO & Corp. Sec. (Age 37)
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 58)
- Mr. Anthony A. Lombardo, Interim Chief Exec. Officer (Age 69)
- Mr. Christopher Duke, Sr. VP & COO
- Mr. Mayo Pujols, Sr. VP of Technical Operations
Has Advaxis been receiving favorable news coverage?
Press coverage about ADXS stock has been trending somewhat positive on Sunday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Advaxis earned a news sentiment score of 0.16 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 45.16 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Advaxis' major shareholders?
Advaxis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.59%) and DAFNA Capital Management LLC (1.33%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.
Which major investors are buying Advaxis stock?
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $1.80.
How big of a company is Advaxis?
Advaxis has a market capitalization of $94.17 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Advaxis employs 108 workers across the globe.
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (ADXS)MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Advaxis (NASDAQ:ADXS) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Advaxis (NASDAQ ADXS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.21%
Institutional Ownership Percentage: 33.90%
Advaxis (NASDAQ ADXS) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|4/2/2018||Robert Petit||Insider||Sell||2,193||$1.62||$3,552.66|| |
|2/2/2018||Anthony A Lombardo||CEO||Sell||32||$2.93||$93.76||92,903|| |
|1/3/2018||Sara Bonstein||CFO||Sell||5,224||$3.18||$16,612.32||229,237|| |
|11/6/2017||Robert Petit||Insider||Sell||3,723||$3.30||$12,285.90||220,917|| |
|11/6/2017||Sara Bonstein||CFO||Sell||3,862||$3.30||$12,744.60||227,908|| |
|11/2/2017||Anthony A Lombardo||CEO||Sell||24||$3.19||$76.56||92,935|| |
|11/2/2017||Robert Petit||Insider||Sell||12,625||$3.19||$40,273.75||237,265|| |
|11/2/2017||Sara Bonstein||CFO||Sell||12,734||$3.19||$40,621.46||244,504|| |
|10/11/2017||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||600,000||$4.30||$2,580,000.00|| |
|9/26/2017||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||1,239,323||$4.42||$5,477,807.66|| |
|3/31/2017||Robert Petit||Insider||Sell||2,454||$8.24||$20,220.96||122,051|| |
|12/30/2016||Sara Bonstein||CFO||Sell||5,520||$7.37||$40,682.40||131,963|| |
|12/20/2016||Thomas J Mckearn||Director||Sell||12,316||$8.08||$99,513.28||69,804|| |
|11/2/2016||Daniel O'connor||CEO||Sell||8,240||$8.32||$68,556.80||303,127|| |
|11/2/2016||Robert Petit||Insider||Sell||2,797||$8.32||$23,271.04||123,659|| |
|10/25/2016||Gregory T Mayes||Insider||Sell||19,162||$8.23||$157,703.26||103,087|| |
|8/9/2016||David Sidransky||Director||Sell||22,808||$15.01||$342,348.08||91,759|| |
|8/8/2016||Richard J Berman||Director||Sell||18,000||$15.21||$273,780.00||66,430|| |
|5/13/2016||Thomas J Mckearn||Director||Sell||4,100||$7.45||$30,545.00||82,120|| |
|5/2/2016||Daniel O'connor||CEO||Sell||8,237||$7.51||$61,859.87||316,661|| |
|5/2/2016||Robert Petit||Insider||Sell||2,785||$7.51||$20,915.35||128,025|| |
|3/31/2016||Robert Petit||Insider||Sell||3,325||$9.13||$30,357.25||131,164|| |
|3/16/2016||Thomas J Mckearn||Director||Sell||14,000||$8.25||$115,500.00||86,220|| |
|2/24/2016||Sara Bonstein||CFO||Sell||15,037||$5.58||$83,906.46||79,980|| |
|1/29/2016||Daniel O'connor||CEO||Sell||8,818||$6.88||$60,667.84||313,394|| |
|1/29/2016||Robert Petit||insider||Sell||3,099||$6.88||$21,321.12||130,557|| |
|10/26/2015||Gregory T Mayes||COO||Sell||19,231||$11.63||$223,656.53||119,821|| |
|10/20/2015||David J Mauro||Insider||Sell||24,586||$10.08||$247,826.88||165,932|| |
|8/24/2015||Adage Capital Partners Gp Llc||Major Shareholder||Buy||300,000||$14.15||$4,245,000.00|| |
|4/30/2015||Adage Capital Partners Gp Llc||Major Shareholder||Buy||500,000||$19.00||$9,500,000.00|| |
|2/18/2015||Adage Capital Partners Gp Llc||Major Shareholder||Buy||684,762||$7.50||$5,135,715.00|| |
|5/9/2014||Richard J Berman||Director||Sell||14,530||$2.63||$38,213.90|| |
|3/31/2014||Daniel O'connor||CEO||Buy||3,333||$3.00||$9,999.00|| |
|10/24/2013||Daniel O'connor||CEO||Buy||13,500||$4.00||$54,000.00|| |
|10/24/2013||Mark J Rosenblum||CFO||Buy||12,000||$4.00||$48,000.00|| |
|10/24/2013||Robert Petit||Insider||Buy||12,800||$4.00||$51,200.00|| |
|10/24/2013||Roni Appel||Director||Buy||12,500||$4.00||$50,000.00|| |
Advaxis (NASDAQ ADXS) News Headlines
| Analysts Expect Advaxis (ADXS) Will Announce Quarterly Sales of $2.43 Million|
www.americanbankingnews.com - May 24 at 2:30 AM
|Zacks: Brokerages Expect Advaxis (ADXS) to Announce -$0.41 Earnings Per Share|
www.americanbankingnews.com - May 22 at 7:20 PM
|Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith ...|
www.nasdaq.com - May 14 at 10:41 AM
|Advaxis (ADXS) Says Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy|
www.streetinsider.com - May 11 at 10:15 AM
|Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent|
finance.yahoo.com - May 11 at 10:15 AM
|Advaxis (ADXS) Expected to Post Quarterly Sales of $2.43 Million|
www.americanbankingnews.com - May 7 at 4:26 AM
|Advaxis (ADXS) Expected to Announce Earnings of -$0.41 Per Share|
www.americanbankingnews.com - May 5 at 9:32 AM
|Advaxis (ADXS) Stock Rating Upgraded by ValuEngine|
www.americanbankingnews.com - May 4 at 3:35 PM
|Form 8-K Advaxis, Inc. For: Apr 23|
www.streetinsider.com - April 24 at 9:10 AM
|BRIEF-Advaxis Announces Executive Leadership Changes|
www.reuters.com - April 23 at 9:36 AM
|Advaxis Announces Executive Leadership Changes|
finance.yahoo.com - April 23 at 9:36 AM
|$2.43 Million in Sales Expected for Advaxis (ADXS) This Quarter|
www.americanbankingnews.com - April 20 at 4:28 AM
|Advaxis (ADXS) Says Preclinical Data Highlighting ADXS-Hot as Immunotherapy Presented in Poster Discussion at ...|
www.streetinsider.com - April 18 at 9:36 AM
|Advaxis (ADXS) Expected to Post Earnings of -$0.41 Per Share|
www.americanbankingnews.com - April 18 at 9:35 AM
|Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting|
finance.yahoo.com - April 17 at 9:22 AM
|Advaxis' (ADXS) "Buy" Rating Reaffirmed at HC Wainwright|
www.americanbankingnews.com - April 17 at 7:39 AM
|Advaxis (ADXS) Rating Lowered to Sell at BidaskClub|
www.americanbankingnews.com - April 15 at 12:36 AM
|Advaxis (ADXS) Downgraded by ValuEngine|
www.americanbankingnews.com - April 8 at 9:37 AM
|What Is The Future Prospect For Healthcare And Advaxis Inc (NASDAQ:ADXS)?|
finance.yahoo.com - April 4 at 4:51 PM
| Analysts Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $2.43 Million|
www.americanbankingnews.com - April 3 at 4:11 AM
|Data Highlighting Advaxis' ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology ...|
www.businesswire.com - April 2 at 10:01 AM
|Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting|
finance.yahoo.com - April 2 at 10:01 AM
|-$0.41 Earnings Per Share Expected for Advaxis, Inc. (ADXS) This Quarter|
www.americanbankingnews.com - April 1 at 7:23 AM
|Advaxis Inc (NASDAQ:ADXS): Does The -36.80% Earnings Drop Reflect A Longer Term Trend?|
finance.yahoo.com - March 27 at 9:12 AM
|Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018|
finance.yahoo.com - March 26 at 10:09 AM
|Advaxis (ADXS) Upgraded to Sell at ValuEngine|
www.americanbankingnews.com - March 25 at 9:16 PM
|Advaxis (ADXS) PT Lowered to $5.00|
www.americanbankingnews.com - March 18 at 12:26 PM
|Edited Transcript of ADXS earnings conference call or presentation 12-Mar-18 8:30pm GMT|
finance.yahoo.com - March 18 at 9:40 AM
|Zacks: Brokerages Anticipate Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $2.43 Million|
www.americanbankingnews.com - March 17 at 8:38 AM
|FY2018 EPS Estimates for Advaxis, Inc. Lifted by Cantor Fitzgerald (ADXS)|
www.americanbankingnews.com - March 16 at 10:48 AM
|Q2 2018 Earnings Estimate for Advaxis, Inc. (ADXS) Issued By Jefferies Group|
www.americanbankingnews.com - March 15 at 7:54 AM
|Zacks: Brokerages Anticipate Advaxis, Inc. (ADXS) Will Post Earnings of -$0.59 Per Share|
www.americanbankingnews.com - March 15 at 5:18 AM
|Advaxis (ADXS) Given a $6.00 Price Target by HC Wainwright Analysts|
www.americanbankingnews.com - March 14 at 10:50 PM
|Advaxis shares drop as cancer-drug study on hold after death - MarketWatch|
www.marketwatch.com - March 14 at 12:18 PM
|Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac ... - Business Wire (press release)|
www.businesswire.com - March 14 at 12:18 PM
|Mid-Day Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares Spike Higher|
www.benzinga.com - March 13 at 4:58 PM
|Advaxis' (ADXS) CEO Tony Lombardo on Q1 2018 Results - Earnings Call Transcript|
seekingalpha.com - March 13 at 10:54 AM
|Advaxis to Present at Upcoming March Conferences|
finance.yahoo.com - March 13 at 10:54 AM
|Advaxis shares drop as cancer-drug study on hold after death|
finance.yahoo.com - March 13 at 10:54 AM
|Advaxis (ADXS) Issues Quarterly Earnings Results|
www.americanbankingnews.com - March 13 at 10:20 AM
|Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Advaxis, and Adverum Biotechnologies|
www.bizjournals.com - March 12 at 4:43 PM
|Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)|
finance.yahoo.com - March 12 at 4:43 PM
|Should You Have Advaxis Inc’s (NASDAQ:ADXS) In Your Portfolio?|
finance.yahoo.com - March 12 at 4:43 PM
|Advaxis reports 1Q loss|
finance.yahoo.com - March 12 at 4:43 PM
|Advaxis, Inc. (ADXS) Short Interest Update|
www.americanbankingnews.com - March 12 at 1:24 AM
|How Do Analysts See Advaxis Inc (NASDAQ:ADXS) Performing Over The Next Few Years?|
finance.yahoo.com - March 9 at 4:54 PM
|Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018|
finance.yahoo.com - March 9 at 10:59 AM
|Advaxis Inc (NASDAQ:ADXS): Is Breakeven Near?|
finance.yahoo.com - March 8 at 10:32 AM
|Advaxis (ADXS) Set to Announce Earnings on Thursday|
www.americanbankingnews.com - March 1 at 1:30 AM
| Brokerages Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $3.03 Million|
www.americanbankingnews.com - February 28 at 1:48 PM
Advaxis (NASDAQ:ADXS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Advaxis (NASDAQ:ADXS) Income Statement, Balance Sheet and Cash Flow Statement
Advaxis (NASDAQ ADXS) Stock Chart for Sunday, May, 27, 2018